Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3311)
All Articles published online
|
Oct 28, 2008 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Clemmesen JO, Giraldi A, Ott P, Dalhoff K, Hansen BA, Larsen FS. Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. World J Gastroenterol 2008; 14(40): 6208-6212 [PMID: 18985812 DOI: 10.3748/wjg.14.6208] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i40/6208.htm |
| Number | Citing Articles |
| 1 |
Jitender Thakur, Sahaj Rathi, Sandeep Grover, Madhu Chopra, Swastik Agrawal, Sunil Taneja, Ajay Duseja, Anil Bhansali, Yogesh K. Chawla, Radha K. Dhiman. Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis. Journal of Clinical and Experimental Hepatology 2019; 9(3): 312 doi: 10.1016/j.jceh.2018.07.007
|
| 2 |
Philipp Schwabl, Wim Laleman. Novel treatment options for portal hypertension. Gastroenterology Report 2017; 5(2): 90 doi: 10.1093/gastro/gox011
|
| 3 |
Rakesh Kumar Jagdish. Sexual dysfunctions and their treatment in liver diseases. World Journal of Hepatology 2022; 14(8): 1530-1540 doi: 10.4254/wjh.v14.i8.1530
|
| 4 |
Amel M.M. Abdel-Hafez, Manal A. Othman. Effect of sildenafil citrate on the structure of rat liver. The Egyptian Journal of Histology 2013; 36(4): 991 doi: 10.1097/01.EHX.0000440847.85696.1c
|
| 5 |
Puneeta Tandon, Irteza Inayat, Michael Tal, Marcelo Spector, Martha Shea, Roberto J. Groszmann, Guadalupe Garcia–Tsao. Sildenafil Has No Effect on Portal Pressure but Lowers Arterial Pressure in Patients With Compensated Cirrhosis. Clinical Gastroenterology and Hepatology 2010; 8(6): 546 doi: 10.1016/j.cgh.2010.01.017
|
| 6 |
Rafael Paternostro, Birgit B. Heinisch, Thomas Reiberger, Mattias Mandorfer, Remy Schwarzer, Berit Seeland, Michael Trauner, Markus Peck‐Radosavljevic, Arnulf Ferlitsch. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver International 2018; 38(8): 1427 doi: 10.1111/liv.13704
|
| 7 |
Susana G. Rodrigues, Yuly P. Mendoza, Jaime Bosch. Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs 2022; 31(8): 825 doi: 10.1080/13543784.2022.2095259
|
| 8 |
Sergi Guixé-Muntet, Sergio Quesada-Vázquez, Jordi Gracia-Sancho. Pathophysiology and therapeutic options for cirrhotic portal hypertension. The Lancet Gastroenterology & Hepatology 2024; 9(7): 646 doi: 10.1016/S2468-1253(23)00438-7
|
| 9 |
Wolfgang Kreisel, Peter Deibert, Limas Kupcinskas, Jolanta Sumskiene, Beate Appenrodt, Susanne Roth, Michaela Neagu, Martin Rössle, Alexander Zipprich, Karel Caca, Arnulf Ferlitsch, Karin Dilger, Ralf Mohrbacher, Roland Greinwald, Tilman Sauerbruch. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Digestive and Liver Disease 2015; 47(2): 144 doi: 10.1016/j.dld.2014.10.018
|
| 10 |
Wolfgang Kreisel, Denise Schaffner, Adhara Lazaro, Jonel Trebicka, Irmgard Merfort, Annette Schmitt-Graeff, Peter Deibert. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. International Journal of Molecular Sciences 2020; 21(17): 6223 doi: 10.3390/ijms21176223
|
| 11 |
A. Friedl, R. Schwarzer, J. Schneeweiss, C. Brössner. Urologische Aspekte bei Patienten mit Leberzirrhose. Der Urologe 2016; 55(1): 63 doi: 10.1007/s00120-015-3978-x
|
| 12 |
Shao-Jung Hsu, Hui-Chun Huang, Chiao-Lin Chuang, Ching-Chih Chang, Ming-Chih Hou, Fa-Yauh Lee, Shou-Dong Lee. Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats. Pharmaceutics 2020; 12(4): 320 doi: 10.3390/pharmaceutics12040320
|
| 13 |
Rakesh Kumar Jagdish, Ahmed Kamaal, Saggere Muralikrishna Shasthry, Jaya Benjamin, Rakhi Maiwall, Ankur Jindal, Ashok Choudhary, Vijayaraghavan Rajan, Vinod Arora, Ankit Bhardwaj, Guresh Kumar, Manoj Kumar, Shiv K. Sarin. Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial. Hepatology International 2023; 17(2): 434 doi: 10.1007/s12072-021-10264-w
|
| 14 |
John J. Reho, Xiaoxu Zheng, Steven A. Fisher. Smooth muscle contractile diversity in the control of regional circulations. American Journal of Physiology-Heart and Circulatory Physiology 2014; 306(2): H163 doi: 10.1152/ajpheart.00493.2013
|
| 15 |
Leonie Halverscheid, Peter Deibert, René Schmidt, Hubert E Blum, Torsten Dunkern, Benedikt HJ Pannen, Wolfgang Kreisel. Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver. BMC Gastroenterology 2009; 9(1) doi: 10.1186/1471-230X-9-69
|
| 16 |
Shuet Fong Neong, Emma O. Billington, Stephen E. Congly. Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management. Hepatology 2019; 69(6): 2683 doi: 10.1002/hep.30359
|
| 17 |
Frank E. Uschner, Kathleen Glückert, Rafael Paternostro, Thorsten Gnad, Robert Schierwagen, Mattias Mandorfer, Fernando Magdaleno, Cristina Ortiz, Katharina Schwarzkopf, Patrick S. Kamath, Carlo Alessandria, Christoph Boesecke, Alexander Pfeifer, Thomas Reiberger, Wolfgang Kreisel, Tilman Sauerbruch, Arnulf Ferlitsch, Jonel Trebicka, Sabine Klein. Combination of phosphodiesterase‐5‐inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver International 2020; 40(9): 2228 doi: 10.1111/liv.14586
|
| 18 |
Alok Kumar, Vivek Saraswat, Gaurav Pande, Rajesh Kumar. Does Treatment of Erectile Dysfunction With PDE 5 Inhibitor Tadalafil Improve Quality of Life in Male Patients With Compensated Chronic Liver Disease? A Prospective Pilot Study. Journal of Clinical and Experimental Hepatology 2022; 12(4): 1083 doi: 10.1016/j.jceh.2022.01.009
|
| 19 |
Hye Jin Yoo, Bora Lee, Eun-Ae Jung, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo. Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis. Hepatology International 2023; 17(2): 452 doi: 10.1007/s12072-021-10270-y
|
| 20 |
Javier Blanco-Rivero, Fabiano E. Xavier. Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases. Current Pharmaceutical Design 2020; 26(30): 3633 doi: 10.2174/1381612826666200403172736
|
| 21 |
Wolfgang Kreisel, Adhara Lazaro, Jonel Trebicka, Markus Grosse Perdekamp, Annette Schmitt-Graeff, Peter Deibert. Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. International Journal of Molecular Sciences 2021; 22(19): 10372 doi: 10.3390/ijms221910372
|
| 22 |
Guanghui Zang, Xv Sun, Yufeng Sun, Yan Zhao, Yang Dong, Kun Pang, Ping Cheng, Meng Wang, Yuli Zheng. Chronic liver diseases and erectile dysfunction. Frontiers in Public Health 2023; 10 doi: 10.3389/fpubh.2022.1092353
|
| 23 |
Batool AbuHalimeh, Michael J. Krowka, Adriano R. Tonelli. Treatment Barriers in Portopulmonary Hypertension. Hepatology 2019; 69(1): 431 doi: 10.1002/hep.30197
|
| 24 |
Denise Schaffner, Adhara Lazaro, Peter Deibert, Peter Hasselblatt, Patrick Stoll, Lisa Fauth, Manfred W Baumstark, Irmgard Merfort, Annette Schmitt-Graeff, Wolfgang Kreisel. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World Journal of Gastroenterology 2018; 24(38): 4356-4368 doi: 10.3748/wjg.v24.i38.4356
|
| 25 |
Peter Hauff, Ulrich Gottwald, Matthias Ocker. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opinion on Investigational Drugs 2015; 24(3): 309 doi: 10.1517/13543784.2015.997874
|
| 26 |
Seohyuk Lee, Saad Saffo. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World Journal of Gastroenterology 2023; 29(1): 61-74 doi: 10.3748/wjg.v29.i1.61
|
| 27 |
Harikumar Nair, Annalisa Berzigotti, Jaime Bosch. Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs 2016; 21(2): 167 doi: 10.1080/14728214.2016.1184647
|
| 28 |
Moein Ala, Razieh Mohammad Jafari, Ahmad Reza Dehpour. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. Fundamental & Clinical Pharmacology 2021; 35(2): 235 doi: 10.1111/fcp.12633
|
| 29 |
Hui Li. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Digestive and Liver Disease 2022; 54(5): 598 doi: 10.1016/j.dld.2021.07.006
|